Karl Fengler

Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Aims One important contributor to the pathogenesis and perpetuation of HFpEF is unfavorable pulse wave reflection, frequently caused by increased arterial stiffness, due to aging and longstanding hypertension. One possible path to address pathological wave reflections is reducing sympathetic overactivity via renal denervation (RDN) with the aim to enhance arterial compliance. We sought to non-invasively quantify pulse wave reflections changes in patients undergoing RDN. Methods Patients who underwent RDN for resistant hypertension were classified as patients with HFpEF and patients without heart failure, the latter of which served as the control group. Pulse wave analysis (PWA) was assessed using a piezoelectric device, and reflection magnitude was quantified by the augmentation index (AIx), and timing by backward transit time (BTT) before and 3 months after RDN. Ambulatory blood pressure was assessed at baseline and after 3 months to adjust for blood pressure changes. Results Of 51 patients, 22 had HFpEF, and 29 served as controls. While baseline values in AIx and BTT were not different between HFpEF and control patients, RDN was associated with a significant decrease in AIx by 5.6% ( p = 0.04) and a significant prolongation of BTT by 17.8 ms ( p = 0.007) in patients with HFpEF. Conversely, no significant changes were observed in control patients for AIx ( p = 0.13) and BTT ( p = 0.56). Conclusions The study observed a beneficial change in the timing and magnitude of central wave reflections in HFpEF after RDN. This implies a dynamic component of arterial stiffness in HFpEF patients and renders large artery stiffness a potential therapeutic target. Graphical Abstract

Year:

2025

BACKGROUND: The SPYRAL HTN-ON MED (Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications)trial showed significant office and nighttime systolic blood pressure (BP) reductions in patients with hypertension following renal denervation (RDN) compared with sham-control patients, despite similar 24-hour BP reductions. We compared antihypertensive medication and BP changes among prespecified subpopulations. METHODS: The multicenter, randomized, sham-controlled, blinded SPYRAL HTN-ON MED trial (n=337) evaluated BP changes after RDN compared with a sham procedure in patients with hypertension prescribed 1 to 3 antihypertensive drugs. Most patients (n=187; 54%) were enrolled outside the United States, while 156 (46%) US patients were enrolled, including 60 (18%) Black Americans. RESULTS: Changes in detected antihypertensive drugs were similar between RDN and sham group patients in the outside US cohort, while drug increases were significantly more common in the US sham group compared with the RDN group. Patients from outside the United States showed significant reductions in office and 24-hour mean systolic BP at 6 months compared with the sham group, whereas BP changes were similar between RDN and sham in the US cohort. Within the US patient cohort, Black Americans in the sham control group had significant increases in medication burden from baseline through 6 months ( P =0.003) but not in the RDN group ( P =0.44). CONCLUSIONS: Patients enrolled outside the United States had minimal antihypertensive medication changes between treatment groups and had significant office and 24-hour BP reductions compared with the sham group. Increased antihypertensive drug burden in the US sham cohort, especially among Black Americans, may have diluted the treatment effect in the combined trial population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02439775.

Year:

2024

BACKGROUND Renal denervation has proven its efficacy to lower blood pressure in comparison to sham treatment in recent randomized clinical trials. Although there is a large body of evidence for the durability and safety of radiofrequency‐based renal denervation, there are a paucity of data for endovascular ultrasound–based renal denervation (uRDN). We aimed to assess the long‐term efficacy and safety of uRDN in a single‐center cohort of patients. METHODS AND RESULTS Data from 2 previous studies on uRDN were pooled. Ambulatory 24‐hour blood pressure measurements were taken before as well as 3, 6, 12, and 24 months after treatment with uRDN. A total of 130 patients (mean age 63±9 years, 24% women) underwent uRDN. After 3, 6, 12, and 24 months, systolic mean 24‐hour ambulatory blood pressure values were reduced by 10±12, 10±14, 8±15, and 10±15 mm Hg, respectively, when compared with baseline ( P <0.001). Corresponding diastolic values were reduced by 6±8, 6±8, 5±9, and 6±9 mm Hg, respectively ( P <0.001). Periprocedural adverse events occurred in 16 patients, and all recovered without sequelae. CONCLUSIONS In this single‐center study, uRDN effectively lowered blood pressure up to 24 months after treatment.

Year:

2023

Collaborators (7)

Kazuomi Kario

-

JAPAN
View details

Felix Mahfoud

Director

University Hospital Basel

SWITZERLAND
View details

Ingrid Hopper

Monash University Malaysia.

AUSTRALIA
View details

Stuart Pocock

Professor of Medical Statistics

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Faisal Sharif

University of Galway

IRELAND
View details

Konstantinos Toutouzas

-

GREECE
View details

Keith C. Ferdinand

-

UNITED STATES
View details